Urogen Pharma Ltd

Urogen Pharma operates with a negative equity position of -$105.47 million and a total asset base of $200.46 million, indicating a high reliance on external financing. The company's liquidity position is mixed, with $110.75 million in cash and equivalents, but this is offset by $126.96 million in long-term debt, resulting in a net cash position of -$16.21 million. The current ratio of 4.01 suggests strong short-term liquidity, but the debt-to-equity ratio of -1.2 highlights the company's leverage and financial risk. Profitability metrics show a mixed picture. The company reported a gross profit of $97.34 million on $109.79 million in revenue, yielding a gross margin of 88.7%. However, operating income was -$124.86 million, and net income was -$153.49 million, indicating significant operational and non-operational losses. Return on equity (ROE) is 1.46%, while return on assets (ROA) is -0.77%, both of which are below industry norms for biotechnology firms. Geographically, Urogen Pharma's revenue is concentrated in the United States, with no material international operations disclosed. The company's product portfolio is centered on its lead product, Viberzi (Vonoprazan), which is used to treat overactive bladder. There are no material revenue contributions from other therapeutic areas or geographic regions. The company's growth trajectory is uncertain. Revenue for the latest period was $109.79 million, but there is no disclosed prior period data to assess year-over-year growth. Analysts have provided a wide range of price targets, from $18 to $45, with a mean of $36.11 and a median of $40.00, suggesting a high degree of uncertainty in the company's future performance. Risk factors include the company's negative equity and high debt load, which could limit its ability to fund operations or pursue new opportunities. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the net cash position is negative after subtracting total debt. The company has not disclosed any recent equity offerings or dilution events, and the dilution potential is currently low. Recent events include the continued commercialization of Viberzi and ongoing research and development activities. The company has not disclosed any material regulatory or legal challenges, but the biotechnology sector is inherently subject to regulatory scrutiny and clinical trial risks. No recent earnings call transcripts or 10-K filings have been provided in the input data to further detail recent developments.